Vandetanib Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 300 mg
Reference Brands: Caprelsa
Category:
Orphan Drugs
Vandetanib inhibits multiple receptor tyrosine kinases, including RET, VEGFR, and EGFR, blocking tumor growth and angiogenesis. It is effective for medullary thyroid cancer, reducing tumor progression and prolonging survival. Benefits include targeted therapy, symptom control, and improved quality of life in advanced thyroid cancer patients.
Vandetanib Tablets is available in Tablets
and strengths such as 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Vandetanib Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Vandetanib Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Vandetanib tablets, marketed as Caprelsa, are approved in the US by the FDA and in the EU via EMA for treating medullary thyroid carcinoma. Regulatory approval requires a comprehensive dossier, including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports rapid approval, safe patient use, and worldwide availability to improve outcomes in advanced thyroid cancer management globally.
Mitul agarwal
Riluzole: Forms, Brands, and Strengths in EU and US
OpenAI GPT-4o mini
Riluzole: Forms, Brands, and Strengths in EU and US
Forms:
Oral Tablets: The primary form for use in amyotrophic lateral sclerosis (ALS).
Brands & Strengths:
US:
Rilutek: (brand name)
Strengths: 50 mg tablets
EU:
Riluzole: (generic and branded options)
Strengths: Similar 50 mg tablets
Summary:
Riluzole is available as 50 mg oral tablets in both the US and EU, supported for slowing ALS progression. Generic formulations and branded Rilutek ensure broad access, supporting disease management in ALS patients worldwide with regional regulatory compliance.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing